3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
4
Lung Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Hematologic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Sarcoma
1
Neuroblastoma
1
Lymphoproliferative Disorders
1
Glioma
1
Adenocarcinoma of Lung
1
Interventions
Magnetic Resonance Spectroscopy
19
Temozolomide
16
Radiotherapy
10
Specimen Handling
7
Blood Specimen Collection
7
Radiation
6
Bevacizumab
5
Nivolumab
4
Cyclophosphamide
4
Biopsy
4
vorasidenib
3
trametinib
3
pembrolizumab
3
olaparib
3
fludarabine
3
dabrafenib
3
Watchful Waiting
3
Surgical Procedures, Operative
3
Magnetic Resonance Imaging
3
Drug Therapy
3
olutasidenib
2
lutetium Lu 177 dotatate
2
fluorodopa F 18
2
fluciclovine F-18
2
entrectinib
2
contrast agent BR1
2
Restraint, Physical
2
Radiosurgery
2
Microdialysis
2
Flucytosine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Glioma
×
capmatinib
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled